Terumo Neuro Unveils Sofia Flow 88 in EMEA Markets

On June 2, 2025, Terumo Neuro, a fully - owned subsidiary of Terumo Corporation, made an announcement regarding the commercial launch of the Sofia Flow 88 neurovascular aspiration catheter in the Europe, Middle East, and Africa (EMEA) region.

Terumo Neuro explained that the Sofia 88 neurovascular aspiration catheter boasts an inner diameter of 0.088 inches. It is engineered to deliver dependable trackability, procedural adaptability, and enhanced control for physicians.

The company mentioned that the introduction of this large - bore catheter in the EMEA market builds upon the well - established reputation of the Sofia catheter series within its stroke treatment portfolio. This portfolio is being showcased at the LINNC Paris 2025 conference, which is taking place from June 2 to 4 in Paris, France.

According to Terumo, the new Sofia 88 catheter serves as a valuable addition to the company's comprehensive stroke solution lineup, enabling a fully integrated strategy that covers aspiration, access, retrieval, and navigation. The Sofia 88 device is not only compatible with the 6 - F Sofia Plus aspiration catheter but also seamlessly integrates into existing aspiration protocols.

The company highlighted that clinical data from the SOFAST registry and the SESAME trial, which evaluated the 6 - F Sofia Plus device as a primary treatment option, yielded impressive results in terms of speed, effectiveness, safety, and overall clinical outcomes.

In June 2024, the company revealed that the findings from the SOFAST study were published online in the Journal of NeuroInterventional Surgery by Dheeraj Gandhi, MD, and his colleagues.

Earlier, on May 13, Terumo Neuro had announced the commercial availability of the Sofia 88 neurovascular support catheter in the United States.